MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation

被引：36

作者：

Chamuleau, M. E. D. ^{[1
]}

Ossenkoppele, G. J. ^{[1
]}

van de Loosdrecht, A. A. ^{[1
]}

机构：

[1] Free Univ Amsterdam, Med Ctr, Dept Haematol, NL-1081 HV Amsterdam, Netherlands

来源：

IMMUNOBIOLOGY | 2006年 / 211卷 / 6-8期

关键词：

CLIP; HLA-DM; HLA-DO; HLA-DR; invariant chain; MHC class II; tumour antigen presentation; tumour immunology; vaccination;

D O I：

10.1016/j.imbio.2006.05.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

MHC class II molecules presenting MHC class II restricted antigens play an important role in the activation of CD4+ T cells, which are the central orchestrating cells of an immune response. This review focuses on the particular role of MHC class II molecules in tumour immunology. The MHC class II antigen presentation pathway and the expression of MHC class II molecules on tumour cells related to clinical outcome is discussed. Improving the MHC class II tumour antigen presentation pathway, for instance by downregulation. of the invariant chain or modulation of HLA-DO expression, offers many opportunities for developing new modalities of immunotherapy. (c) 2006 Elsevier GmbH. All rights reserved.

引用

页码：619 / 625

页数：7

共 52 条

[1]

CD4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome [J].

Ansell, SM ;

Stenson, M ;

Habermann, TM ;

Jelinek, DF ;

Witzig, TE .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :720-726

[2]

Armstrong TD, 1998, J IMMUNOL, V160, P661

[3]

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity [J].

Armstrong, TD ;

Clements, VK ;

Martin, BK ;

Ting, JPY ;

OstrandRosenberg, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6886-6891

[4]

Aids-related malignancies [J].

Boshoff, C ;

Weiss, R .

NATURE REVIEWS CANCER, 2002, 2 (05) :373-382

[5]

CANCER - A BIOLOGICAL APPROACH .3. VIRUSES ASSOCIATED WITH NEOPLASTIC CONDITIONS [J].

BURNET, M .

BMJ-BRITISH MEDICAL JOURNAL, 1957, 1 (APR13) :841-846

[6]

Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum [J].

Busch, R ;

Cloutier, I ;

Sekaly, RP ;

Hammerling, GJ .

EMBO JOURNAL, 1996, 15 (02) :418-428

[7]

The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined Immunodeficient mice [J].

Carlo-Stella, C ;

Di Nicola, M ;

Turco, MC ;

Cleris, L ;

Lavazza, C ;

Longoni, P ;

Milanesi, M ;

Magni, M ;

Ammirante, M ;

Leone, A ;

Nagy, Z ;

Gioffrè, WR ;

Formelli, F ;

Gianni, AM .

CANCER RESEARCH, 2006, 66 (03) :1799-1808

[8]

Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome [J].

Chamuleau, MED ;

Souwer, Y ;

van Ham, SM ;

Zevenbergen, A ;

Westers, TM ;

Berkhof, J ;

Meijer, CJLM ;

van de Loosdrecht, AA ;

Ossenkoppele, GJ .

CANCER RESEARCH, 2004, 64 (16) :5546-5550

[9]

Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development [J].

Chen, XJ ;

Laur, O ;

Kambayashi, T ;

Li, SY ;

Bray, RA ;

Weber, DA ;

Karlsson, L ;

Jensen, PE .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (08) :1053-1062

[10]

SPECIFICITY AND PROMISCUITY AMONG NATURALLY PROCESSED PEPTIDES BOUND TO HLA-DR ALLELES [J].

CHICZ, RM ;

URBAN, RG ;

GORGA, JC ;

VIGNALI, DAA ;

LANE, WS ;

STROMINGER, JL .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (01) :27-47

← 1 2 3 4 5 6 →